Status:
TERMINATED
Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech - FUTURE Extension
Lead Sponsor:
Novoic Limited
Conditions:
Alzheimer Disease
Preclinical Alzheimer's Disease
Eligibility:
All Genders
50-85 years
Brief Summary
The primary objective of the study is to evaluate whether a set of algorithms analysing acoustic and linguistic patterns of speech, can predict change in PACC5 between baseline and +12 month follow up...
Eligibility Criteria
Inclusion
- Subjects are fully eligible for and have completed the AMYPRED (Amyloid Prediction in early stage Alzheimer's disease from acoustic and linguistic patterns of speech) study.
- (See https://clinicaltrials.gov/ct2/show/NCT04828122)
- Subject consents to take part in FUTURE extension study.
Exclusion
- Subject hasn't completed the full visit day in the AMYPRED study.
Key Trial Info
Start Date :
November 19 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 7 2024
Estimated Enrollment :
67 Patients enrolled
Trial Details
Trial ID
NCT04846426
Start Date
November 19 2020
End Date
June 7 2024
Last Update
June 14 2024
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Re:Cognition Health
Birmingham, United Kingdom, B16 8LT
2
Re:Cognition Health
Guildford, United Kingdom, GU2 7YD
3
Re:Cognition Health
London, United Kingdom, W1G9JF
4
Re:Cognition Health
Plymouth, United Kingdom, PL68BT